Physician profile
Nikya Watson
NPI 1932811304
$1,890.28
in general payments reported to CMS, 2019-2025
23 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $893 · 2024: $611 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,890.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $653.85 | 2023-2025 | |
| Gilead Sciences, INC. | $201.57 | 2023 | Vemlidy, Epclusa |
| Exact Sciences Corporation | $154.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $152.67 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Lucid Diagnostics INC. | $115.73 | 2023 | |
| Novartis Pharmaceuticals Corporation | $66.93 | 2024-2025 | |
| Hologic Sales and Service, LLC | $66.37 | 2023 | Thinprep 2000 Processor, Aptima |
| Amgen INC. | $58.78 | 2023-2024 | Otezla, Repatha |
| Phadia US INC. | $57.57 | 2023-2025 | Immunocap |
| Pfizer INC. | $56.31 | 2024-2025 | |
| Novo Nordisk INC | $38.63 | 2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $31.30 | 2024 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $29.84 | 2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $29.80 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $28.68 | 2024-2025 | Shingrix, Arexvy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.26 | 2024 | Lifevest |
| Merck Sharp & Dohme LLC | $21.54 | 2024 | Gardasil 9, Gardasil, M-M-R II |
| Nevro Corp. | $19.16 | 2024 | Senza |
| Saluda Medical Americas, INC. | $18.90 | 2025 | Evoke |
| Corcept Therapeutics | $18.89 | 2025 | Korlym |
| Ardelyx, INC. | $15.29 | 2024 | Ibsrela |
| Seqirus USA INC | $14.38 | 2024 | Flucelvax, Fluad |
| Bayer Healthcare Pharmaceuticals INC. | $13.67 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikya Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.